<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00104936</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-26021 -22021</org_study_id>
    <secondary_id>EORTC-26021</secondary_id>
    <secondary_id>EORTC-22021</secondary_id>
    <secondary_id>CAN-NCIC-EORTC-26021</secondary_id>
    <nct_id>NCT00104936</nct_id>
  </id_info>
  <brief_title>Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery</brief_title>
  <official_title>Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Radiosurgery may be&#xD;
      able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving&#xD;
      radiation therapy or radiosurgery after surgery may kill any remaining tumor cells. It is not&#xD;
      yet known whether radiation therapy or radiosurgery is more effective than observation alone&#xD;
      in treating benign meningioma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying radiation therapy or radiosurgery to see&#xD;
      how well they work compared to observation alone in treating patients with newly diagnosed,&#xD;
      benign meningioma that has been partially removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare progression-free survival of patients with newly diagnosed, incompletely&#xD;
           resected, benign intracranial grade I meningioma treated with adjuvant conventional&#xD;
           fractionated radiotherapy or radiosurgery vs observation only.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the quality of life of patients treated with these regimens.&#xD;
&#xD;
        -  Compare overall survival of patients treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence of a second surgery in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the incidence of acute and long-term neurotoxicity in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      post-surgery MRI staging (3 vs 4 vs 5), skull base location (yes vs no), age (&lt; 60 vs â‰¥ 60),&#xD;
      and participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo observation only.&#xD;
&#xD;
        -  Arm II: Within 4-7 months after surgery, patients undergo conventional fractionated&#xD;
           radiotherapy once daily, 5 days a week for 6 weeks OR a single treatment of high-dose&#xD;
           radiosurgery in the absence of unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, at 6 months after randomization, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3 and 6 months after&#xD;
      randomization and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 478 patients (239 per treatment arm) will be accrued for this&#xD;
      study within 3-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a second surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute neurotoxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term neurotoxicity</measure>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed newly diagnosed benign intracranial meningioma&#xD;
&#xD;
               -  WHO grade I&#xD;
&#xD;
               -  Any location except orbital meningioma&#xD;
&#xD;
          -  Mitotic index &lt; 4 (total counts per 10 high-power field) AND MIB-1 labeling index &lt; 4%&#xD;
&#xD;
          -  The following histologies are not allowed (i.e., WHO grade II or III):&#xD;
&#xD;
               -  Atypical&#xD;
&#xD;
               -  Clear cell&#xD;
&#xD;
               -  Choroid&#xD;
&#xD;
               -  Rhabdoid&#xD;
&#xD;
               -  Papillary&#xD;
&#xD;
               -  Anaplastic&#xD;
&#xD;
          -  Must have undergone non-radical resection* within the past 7 months&#xD;
&#xD;
               -  Post-operative MRI (performed 4 months after surgery) demonstrating stages 3, 4,&#xD;
                  or 5 NOTE: *Biopsy only is considered non-radical resection and may be classified&#xD;
                  as stage 4 or 5 according to tumor volume&#xD;
&#xD;
          -  No brain invasion&#xD;
&#xD;
          -  No hemangiopericytoma&#xD;
&#xD;
          -  No fibrous dysplasia or intra-osseous meningioma&#xD;
&#xD;
          -  No multiple meningiomas or meningiomatosis&#xD;
&#xD;
          -  Not part of neurofibromatosis type II&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No serious congestive heart failure&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy except basal cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other disease that would preclude 5-year follow up after study completion&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance or study follow up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the meninges or brain that would preclude study treatment&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior randomization to this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John G. Wolbers, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Center Rotterdam at Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Miralbell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Cantonal Universitaire de Geneve</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolando F. Del Maestro, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Montreal Neurological Institute and Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Souhami, MD</last_name>
    <role>Study Chair</role>
    <affiliation>McGill Cancer Centre at McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiotherapeutisch Instituut-(Riso)</name>
      <address>
        <city>Deventer</city>
        <zip>7400 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Rotterdam at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>March 3, 2005</study_first_submitted>
  <study_first_submitted_qc>March 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2005</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult grade I meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

